15 Oct 2021 07:00
Sensyne Health and OMNY Health Sign Teaming Agreement to Support Breakthrough Research Through the Power of Real World Data and AI
Sensyne and OMNY will collaborate to develop new proposals to life sciences companies and healthcare providers to use real world data and advanced analytical tools to improve patient outcomes and accelerate the development of new medicines
The Teaming Agreement allows OMNY to engage Sensyne's data analytics tools and consulting services and provides Sensyne with the potential to access OMNY Health's 22 million de-identified patient records
Dover, DE and Atlanta, GA. Oxford, U.K. October 15, 2021: Sensyne Health plc (LSE: SENS) ("Sensyne"), the ethical Clinical AI company, and OMNY Health ("OMNY"), the largest US-based real world data network, today announced a strategic teaming relationship.
The arrangement establishes a nimble framework under which Sensyne can contract for access to OMNY Health's platform of more than 22 million de-identified patient records across all therapeutic areas in support of Sensyne's data analytics work for life science companies. In addition, Sensyne and OMNY have agreed to work together on commercial projects for life science clients to advance and accelerate ethical medical research. By bringing biopharma clients a joint offering with OMNY real-world data and Sensyne machine learning expertise, both companies-and their health system partners-will have more opportunities to support important life sciences research.
The OMNY data network complements Sensyne's existing global medical research dataset of 22.1 million patients, ethically sourced through strategic partnerships with US health systems and the UK's National Health Service (NHS) trusts. With a data network that spans over 50,000 providers across 40 states, OMNY's data platform also offers control, security, and data governance to maximize the utility of information while maintaining compliance with US regulations. Sensyne will now have a new avenue to access an additional 22 million unique patient records, significantly enhancing the scale of real world data on which Sensyne can apply its advanced machine learning and bringing the combined total of de-identified patient data available for its research to over 44m patients.
Derek Baird, President, North America, Sensyne Health said:
"This relationship has been forged on a mutual belief in the power of real-world data to support breakthrough insights and discoveries. The team at OMNY, like us, appreciate the complexity of working with longitudinal clinical records, and the trust that health systems place in our companies to analyse de-identified patient data in an ethical, secure, and responsible way. We share common philosophies and missions, and complementary approaches in responsibly using real-world data to accelerate life science research for clients. This is an exciting alliance, and we are thrilled to be working together."
Mitesh Rao, MD, CEO, OMNY Health said:
"OMNY Health embraces the opportunity to work with Sensyne Health's world-class machine learning team and data science professionals, and is thrilled for Sensyne to join the platform. We aim to revolutionize the healthcare ecosystem through our equality-driven data network while unlocking transformative real world data partnerships across the life sciences industry. This collaboration with Sensyne Health creates even greater possibilities to apply emerging technologies to the unparalleled data we've assembled, enabling both companies to ethically innovate on behalf of our respective partners, and most importantly, to create better outcomes for patients."
Sensyne is working with life science partners on different types of research projects across multiple disease areas. The actionable insights from OMNY's longitudinal patient data sets will help them with synthetic control arms, patient stratification, patient identification and selection, plus important late-phase clinical trial design, commercialisation, and health economic pricing decisions.
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com) | +44 (0) 330 058 1845 |
Lord (Paul) Drayson PhD FREng, Chief Executive Officer | |
Dr Richard Pye, Chief Financial Officer | |
Peel Hunt LLP (Nominated Adviser and Joint Broker) |
+ 44 (0) 20 7418 8900 |
Dr Christopher Golden | |
James Steel | |
Victoria Erskine | |
Liberum (Joint Broker) | + 44 (0) 20 3100 2000 |
Bidhi Bhoma | |
Euan Brown | |
Consilium Strategic Communications | +44 (0) 77 0286 8207 |
Mary-Jane Elliott | |
Jessica Hodgson | |
CSCSensynehealth@consilium-comms.com |
Notes to editors
About Sensyne Health: www.sensynehealth.com
Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems. The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers remote patient monitoring and real-time decision-making systems for healthcare organizations and their patients. In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.
About OMNY: www.omnyhealth.com
OMNY Health connects patients, providers, and life sciences companies through data and insights to accelerate life-changing innovation. Our secure platform enables life sciences organizations to engage in collaborative data and research partnerships efficiently, compliantly, and at scale. OMNY Health is dedicated to reimagining a future of patient-centered and evidence-based care driven by a connected data ecosystem that links all parts of the healthcare experience.